NLRP3 inflammasome inhibitor Mcc950 ameliorates synaptic plasticity deficits in a McGill-R-Thy1-APP rat model of AD, indicating the damaging effects of NLRP3 inflammasome in synaptic dysfunction (Qi et al., 2018). Here, APP is linked to Alzheimer disease.